Incidence, severity, and associated risk factors for amyloid-related imaging abnormalities in anti-amyloid monoclonal antibody therapy for early Alzheimer's disease: a systematic review and meta-analysis.
Neurol SciOct 2, 2026 (epub)
Markus A Martinez Holst, Ana Maria Sierra Valiente, Carlos A Garcia-Becerra
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the incidence and risk factors for amyloid-related imaging abnormalities (ARIA) in 12,610 patients with early Alzheimer's disease receiving anti-amyloid monoclonal antibody therapy. The pooled incidence was 5.4% for ARIA-E and 10.27% for ARIA-H, with most cases being asymptomatic and mild to moderate in severity.
Key findings
- Pooled incidence of ARIA-E was 5.4% and ARIA-H was 10.27%.
- ApoE 4 homozygotes had an odds ratio of 5.12 for ARIA-E occurrence.
- Higher monoclonal antibody dosage was associated with an odds ratio of 2.0 for ARIA-E.
- Symptomatic ARIA-E was more common in ApoE 4 carriers with an odds ratio of 1.52 to 3.68.
Why it matters
Understanding the incidence and risk factors for ARIA is crucial for clinicians managing early Alzheimer's disease, as it informs patient monitoring and risk stratification during anti-amyloid monoclonal antibody therapy.